111 Capital’s AbbVie ABBV Stock Holding History

111 Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,504	Closed	-$1.63M	–	489
2026 Q1	$1.63M	Buy	7,504 +62	+0.8%	+$13.8K	0.4%	46
2025 Q4	$1.7M	Buy	7,442 +3,031	+69%	+$690K	0.37%	50
2025 Q3	$1.02M	Sell	4,411 -15,143	-77%	-$3.08M	0.19%	107
2025 Q2	$3.63M	Buy	19,554 +9,484	+94%	+$1.76M	0.62%	28
2025 Q1	$2.11M	Buy	+10,070	New	+$1.96M	0.41%	45

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

111 Capital's ABBV Position: Q2 2026 in Review

111 Capital sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 7,504 shares — an estimated $1.63M sold.

111 Capital first reported a position in ABBV in Q1 2025 and held it in 5 quarters. The position peaked at $3.63M in Q2 2025. 4,207 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

111 Capital reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
111 Capital sold 7,504 AbbVie shares in Q2 2026, an estimated $1.63M.
111 Capital first reported a position in AbbVie in Q1 2025 and held it in 5 quarters.
111 Capital's AbbVie position peaked at $3.63M in Q2 2025.
4,207 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on 111 Capital's 13F filing for Q2 2026, filed 5 Aug 2026.